MSC vs HSCT for Scleroderma (Systemic Sclerosis): what the registries show

Side by side

The condition underneath the comparison

Systemic sclerosis combines vascular injury, autoimmunity and progressive fibrosis of skin and internal organs. Autologous haematopoietic transplantation has controlled trial evidence in severe rapidly progressive disease — with real treatment-related mortality — making this an indication where risk-benefit must be stated explicitly rather than implied.

MSC: what it is

Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.

HSCT: what it is

Haematopoietic transplantation is the oldest and most consequential cell therapy in medicine, with conditioning regimens that carry real mortality risk alongside genuine disease-modifying power. Registrations under this label therefore mix decades-old standard-of-care protocols with newer autoimmune-reset trials, and the risk profile is nothing like that of an outpatient infusion.

Maturity difference

MSC has 0 Phase 3/4 records and 5 completed studies; HSCT has 4 and 10. Where both sit early on the ladder, the honest answer to "which works better" is that registrations cannot tell you.

Leading MSC studies

Leading HSCT studies

The honest comparison

Head-to-head trials putting these two approaches in the same protocol are rare or absent for most conditions. Comparing counts from separate registry queries shows where research effort went — driven by cost, regulation and sponsor interest as much as by biology. Anyone presenting one column of this table as proof of superiority is overreading it.

Frequently asked

Is MSC better than HSCT for Scleroderma (Systemic Sclerosis)?

The registries cannot answer that. They show research volume and maturity, not comparative effectiveness: 11 vs 24 registered records (2026-08-29).

Which has more late-stage research for Scleroderma (Systemic Sclerosis)?

MSC: 0 Phase 3/4 records. HSCT: 4.

Can a clinic offer both?

Some do, which is itself worth questioning — a provider offering every modality for every condition is describing a business model, not a treatment rationale.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.